Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation.

Clinical therapeutics - 1 Nov 2013

Vannaprasaht Suda, Reungjui Sirirat, Supanya Darika, Sirivongs Dhavee, Pongskul Cholatip, Avihingsanon Yingyos, Tassaneeyakul Wichittra

Abstract excerpt

BACKGROUND: Cytochrome P450 (CYP) 3A4 and 3A5 are major isoforms involved in the metabolism of tacrolimus, with the CYP3A5 gene being more polymorphic. It is hypothesized that individual variation in the metabolism of tacrolimus drug may result from genetic polymorphism of CYP3A5. It has been reported that the clearance of tacrolimus in patients with the CYP3A5*1 allele was ~2.5-fold greater than that in those...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B
Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP3A

Share to Dose-Response Relationship, Drug

Share to Immunosuppressive Agents

Share to Kidney Transplantation

Share to Tacrolimus

Source

Identifiers

PMID: 24120259
DOI: 10.1016/j.clinthera.2013.08.019

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation.PMID 24120259Read ↗

Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation.Semantic proximity Read ↗

Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients.Semantic proximity Read ↗

The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.Semantic proximity Read ↗

Influence of CYP3A4*22 and CYP3A5*3 combined genotypes on tacrolimus dose requirements in Egyptian renal transplant patients.Semantic proximity Read ↗

Genetic polymorphisms and individualized tacrolimus dosing.Semantic proximity Read ↗

Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients.Semantic proximity Read ↗

Factors affecting the long-term response to tacrolimus in renal transplant patients: pharmacokinetic and pharmacogenetic approach.Semantic proximity Read ↗

Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus.Semantic proximity Read ↗

Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.Semantic proximity Read ↗

Melding Pharmacogenomic Effect of MDR1 and CYP3A5 Gene Polymorphism on Tacrolimus Dosing in Renal Transplant Recipients in Northern IndiaSemantic proximity Read ↗

The importance of MDR1 gene polymorphisms for tacrolimus dosage.Semantic proximity Read ↗

Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.